Funder
National Natural Science Foundation of China
Subject
Health Informatics,Computer Science Applications,Software
Reference32 articles.
1. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial;Brahmer;Lancet Oncol.,2017
2. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;The Lancet,2017
3. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases;Vokes;Ann. Oncol.,2018
4. Therapy for stage IV non–small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update;Hanna;J. Clin. Oncol.,2020
5. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in the treatment of advanced non-small cell lung cancer;Chen;Discov. Med.,2018
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献